Best Practice & Research Clinical Rheumatology
Volume 20, Issue 6 , Pages 1139-1157 , December 2006

Viral causes of arthritis

  • Rauli Franssila, MD, PhD (Research Fellow)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +358 9 1912 6676; Fax: +358 9 1912 6491.
    • ,
  • Klaus Hedman, MD (Professor of Virology)

References 

  1. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005;23:3876–3886
  2. Lund KD, Chantler JK. Mapping of genetic determinants of rubella virus associated with growth in joint tissue. Journal of Virology. 2000;74:796–804
  3. Takahashi Y, Murai C, Shibata S, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proceedings of the National Academy of Science USA. 1998;95:8227–8232
  4. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annual Review of Immunology. 2001;19:163–196
  5. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Current Opinion in Pharmacology. 2004;4:386–391
  6. Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood. 2002;15:2913–2921
  7. Slaughter L, Carson DA, Jensen FC, et al. In vitro effects of Epstein-Barr virus on peripheral blood mononuclear cells from patients with rheumatoid arthritis and normal subjects. Journal of Experimental Medicine. 1978;148:1429–1434
  8. Inman RD, Chiu B, Hamilton NC. Analysis of immune complexes in rheumatoid arthritis for Epstein-Barr virus antigens reveals cross-reactivity of viral capsid antigen and human IgG. Journal of Immunology. 1987;138:407–412
  9. Birkenfeld P, Haratz N, Klein G, Sulitzeanu D. Cross-reactivity between the EBNA-1 p107 peptide, collagen, and keratin: implications for the pathogenesis of rheumatoid arthritis. Clinical Immunology and Immunopathology. 1990;54:14–25
  10. Fox DA. The role of T-cells in the immunopathogenesis of rheumatoid arthritis. Arthritis and Rheumatism. 1997;40:598–609
  11. McClain MT, Heinlen LD, Dennis GJ, et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nature Medicine. 2005;11:85–89
  12. Poole BD, Scofield RH, Harley JB, James JA. Epstein–Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity. 2006;39:63–70
  13. Pratesi F, Tommasi C, Anzilotti C, et al. Deiminated Epstein–Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis and Rheumatism. 2006;54:733–741
  14. Girbal-Neuhauser E, Durieux JJ, Arnaud M, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. Journal of Immunology. 1999;162:585–594
  15. Baeten D, Peene I, Union A, et al. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis and Rheumatism. 2001;44:2255–2262
  16. Van Gaalen F, Ioan-Facsinay A, Huizinga TW, Toes RE. The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis. Journal of Immunology. 2005;175:5575–5580
  17. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and Rheumatism. 2000;43:155–163
  18. Bizzaro N, Mazzanti G, Tonutti E, et al. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clinical Chemistry. 2001;47:1089–1093
  19. Kyewski B, Klein L. A central role for central tolerance. Annual Review of Immunology. 2006;24:571–606
  20. Wucherpfenning KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 1995;80:695–705
  21. Hemmer B, Vergelli M, Gran B, et al. Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. Journal of Immunology. 1998;160:3631–3636
  22. Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nature Immunology. 2002;3:940–943
  23. Mycko MP, Waldner H, Anderson DE, et al. Cross-reactive TCR responses to self antigens presented by different MHC class II molecules. Journal of Immunology. 2004;173:1689–1698
  24. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-γ. Annual Review of Immunology. 1997;15:749–795
  25. Spellberg B, Edwards JE. Type 1/Type 2 immunity in infectious diseases. Clinical Infectious Diseses. 2001;32:76–102
  26. Sewell AK, Price DA, Teisserenc H, et al. IFN-gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase. Journal of Immunology. 1999;162:7075–7079
  27. Fujihara M, Takahashi TA, Azuma M, et al. Decreased inducible expression of CD80 and CD86 in human monocytes after ultraviolet-B irradiation: its involvement in inactivation of allogenecity. Blood. 1996;87:2386–2393
  28. Moudgil KD, Sercarz EE. Understanding crypticity is the key to revealing the pathogenesis of autoimmunity. Trends in Immunology. 2005;26:355–359
  29. Salemi S, Caporossi AP, Boffa L, et al. HIVgp120 activates autoreactive CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing. Journal of Experimental Medicine. 1995;181:2253–2257
  30. Warnock MG, Goodacre JA. Cryptic T-cell epitopes and their role in the pathogenesis of autoimmune diseases. British Journal of Rheumatology. 1997;36:1144–1150
  31. Boyer O, Saadoun D, Abriol J, et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood. 2004;103:3428–3430
  32. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. The New England Journal of Medicine. 1978;298:869–871
  33. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis and Rheumatism. 1987;30:1205–1213
  34. Roudier J, Petersen J, Rhodes GH, et al. Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein–Barr virus glycoprotein gp110. Proceedings of the National Academy of Sciences USA. 1989;13:5104–5108
  35. La Cava A, Nelson JL, Ollier WE, et al. Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. Journal of Clinical Investigation. 1997;100:658–663
  36. Massa M, Mazzoli F, Pignatti P, et al. Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein–Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis and Rheumatism. 2002;46:2721–2729
  37. Heise MT, Simpson DA, Johnston RE. Sindbis-group alphaviruses replication in periosteum and endosteum of long bones in adult mice. Journal of Virology. 2000;74:9294–9299
  38. Zare FM, Bokarewa N, Nenonen T, et al. Arthritogenic properties of double-stranded (viral) RNA. Journal of Immunology. 2004;172:5656–5663
  39. Magnusson M, Zare F, Tarkowski A. Requirement of type I interferon signalling for arthritis triggered by double-stranded RNA. Arthritis and Rheumatism. 2006;54:148–157
  40. Ray NB, Nieva DR, Seftor EA, et al. Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts. Arthritis and Rheumatism. 2001;44:1582–1586
  41. Lu J, Zhi N, Wong S, Brown KE. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. Journal of Infectious Diseases. 2006;193:582–590
  42. Enders M, Schalasta G, Baisch C, et al. Human parvovirus B19 infection during pregnancy – value of modern molecular and serological diagnostics. Journal of Clinical Virology. 2006;35:400–406
  43. Söderlund M, von Essen R, Haapasaari J, et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet. 1997;349:1063–1065
  44. Norja P, Hokynar K, Aaltonen LM, et al. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proceedings of the National Academy of Science USA. 2006;103:7450–7453
  45. Heegaard ED, Brown KE. Human parvovirus B19. Clinical Microbiology Reviews. 2002;15:485–505
  46. Nguyen QT, Sifer C, Scheiner V, et al. Novel human erythrovirus associated with transient aplastic anemia. Journal of Clinical Microbiology. 1999;37:2483–2487
  47. Hokynar K, Söderlund-Venermo M, Pesonen M, et al. A new parvovirus genotype persistent in human skin. Virology. 2002;302:224–228
  48. Servant A, Laperche S, Lallemand F, et al. Genetic diversity within human erythroviruses: identification of three genotypes. Journal of Virology. 2002;76:9124–9134
  49. Candotti D, Etiz N, Parsyan A, Allain J-P. Identification and characterization of persistent human erythrovirus infection in blood donor samples. Journal of Virology. 2004;78:12169–12178
  50. Noyola DE, Padilla-Ruiz ML, Obregón-Ramos MG, et al. Parvovirus B19 infection in medical students during a hospital outbreak. Journal of Medical Microbiology. 2004;53:141–146
  51. Woolf AD, Campion G, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Archives of Internal Medicine. 1989;149:1153–1156
  52. Kurtzman G, Frickhofen N, Kimball J, et al. Pure red cell aplasia of 10 years’ duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. The New England Journal of Medicine. 1989;321:519–523
  53. Faden H, Gary GW, Anderson LJ. Chronic parvovirus infection in a presumably Immunologically healthy woman. Clinical Infectious Diseases. 1992;15:595–597
  54. Kuhl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112:1965–1970
  55. Kytö V, Vuorinen T, Saukko P, et al. Cytomegalovirus infection of the heart is common in patients with fatal myocarditis. Clinical Infectious Diseases. 2005;40:683–688
  56. Tschope C, Bock CT, Kasner M, et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation. 2005;111:879–886
  57. Nocton JJ, Miller LC, Tucker LB, Schaller JG. Human parvovirus B19-associated arthritis in children. Journal of Pediatrics. 1993;122:186–190
  58. Kerr J, McCoy M, Burke B, et al. Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection. Journal of Clinical Pathology. 2003;56:725–727
  59. Kerr JR, Cunniffe VS, Kelleher P, et al. Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis. Journal of Medical Virology. 2004;74:147–155
  60. Kerr JR, Mattey DL, Thomson W, et al. Association of symptomatic acute human parvovirus B19 infection with human leukocyte antigen class I and II alleles. Journal of Infectious Disease. 2002;186:447–452
  61. Kerr JR, Kaushik N, Fear D, et al. Single-nucleotide polymorphism associated with symptomatic infection and differential human gene expression in healthy seropositive persons each implicate the cytoskeleton, integrin signalling, and oncosuppression in the pathogenesis of human parvovirus B19 infection. Journal of Infectious Diseases. 2005;192:276–286
  62. White DG, Mortimer PP, Blake DR, et al. Human parvovirus arthropathy. Lancet. 1985;1:419–421
  63. Naides SJ, Scharosch LL, Foto F, Howard EJ. Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis and Rheumatism. 1990;33:1297–1309
  64. Cohen BJ, Buckley MM, Clewley JP, et al. Human parvovirus infection in an early rheumatoid and inflammatory arthritis. Annals of the Rheumatic Diseases. 1986;45:832–838
  65. Tyndall A, Jelk W, Hirsch HH. Parvovirus B19 and erosive polyarthritis. Lancet. 1994;343:480–481
  66. Luzzi GA, Kurtz JB, Chapel H. Human parvovirus arthropathy and rheumatoid factor. Lancet. 1985;i:1218
  67. Naides SJ, Field EH. Transient rheumatoid factor positivity in acute human parvovirus B19 infection. Archives of Internal Medicine. 1988;148:2587–2589
  68. Dijkmans BA, van Elsacker-Niele AM, Salimans MM, et al. Human parvovirus B19 DNA in synovial fluid. Arthritis and Rheumatism. 1988;31:279–281
  69. Kandolf R, Kirschner P, Hofschneider PH, Vischer TL. Detection of parvovirus in a patient with ‘reactive arthritis’ by in situ hybridisation. Clinical Rheumatology. 1989;8:398–401
  70. Saal JG, Steidle M, Einsele H, et al. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatology International. 1992;12:147–151
  71. Mehraein Y, Lennerz C, Ehlhardt S, et al. Detection of parvovirus B19 capsid proteins in lymphocytic cells in synovial tissue of autoimmune chronic arthritis. Modern Pathology. 2002;16:811–817
  72. Klouda PT, Corbin SA, Bradley BA, et al. HLA and acute arthritis following human parvovirus infection. Tissue Antigens. 1986;28:318–319
  73. Gendi NS, Gibson K, Wordsworth BP. HLA type and hypocomplementaemia on the expression of parvovirus arthritis: one year follow up of an outbreak. Annals of the Rheumatic Diseases. 1996;55:63–65
  74. Chen Y-S, Chou P-S, Li S-N, et al. Parvovirus B19 infection in patients with rheumatoid arthritis in Taiwan. Journal of Rheumatology. 2006;33:887–891
  75. Takasawa N, Munakata Y, Ishii KK, et al. Human parvovirus B19 transgenic mice become susceptible to polyarthritis. Journal of Immunology. 2004;173:4675–4683
  76. Moffat S, Tanaka N, Tada K, et al. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. Journal of Virology. 1996;70:8485–8491
  77. Fu Y, Ishii KK, Munakata Y, et al. Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. Journal of Virology. 2002;76:5395–5403
  78. Shingu M, Nagai Y, Isayama T, et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes, and TIMP production by synovial cells and endothelial cells. Clinical and Experimental Immunology. 1993;94:145–149
  79. Lunardi C, Tiso M, Borgato L, et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. European Journal of Immunology. 1998;28:936–948
  80. Török TJ. Unusual Clinical manifestations reported in patients with parvovirus B19 infection. In:  Anderson LJ,  Young NS editor. Human parvovirus B19. Monographs in Virology. 1997;p. 61–92[Basel, Karger]
  81. Speyer I, Breedveld FC, Dijkmans BAC. Human parvovirus B19 infection is not followed by inflammatory joint disease during long term follow-up. A retrospective study of 54 patients. Clinical and Experimental Rheumatology. 1998;16:576–578
  82. Peterlana D, Puccetti A, Beri R, et al. The presence of parvovirus B19 VP and NS1 genes in synovium is not correlated with rheumatoid arthritis. Journal of Rheumatology. 2003;30:1907–1910
  83. Lehmann HW, Kuhner L, Beckenlehner K, et al. Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence. Journal of Clinical Virology. 2002;25:135–143
  84. Loizou S, Cazabon JK, Walport MJ, et al. Similarities of specificity and cofactor dependence in serum antiphospolipid antibodies from patients with human parvovirus B19 infection and those with systemic lupus erythematosus. Arthritis and Rheumatism. 1997;40:103–108
  85. Von Landenberg P, Lehmann HW, Knöll A, et al. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis and Rheumatism. 2003;7:1939–1947
  86. Chou TN, Hsu TC, Chen RM, et al. Parvovirus B19 infection associated with the production of antineutrophil cytoplasmic antibody (ANCA) and anticardiolipin antibody (aCL). Lupus. 2000;9:551–554
  87. Chassagne P, Mejjad O, Gourmelen O, et al. Exacerbation of systemic lupus erythematosus during human parvovirus B19 infection. British Journal of Rheumatology. 1993;32:158–159
  88. Vigeant P, Ménard HA, Boire G. Chronic modulation of the autoimmune response following parvovirus B19 infection. Journal of Rheumatology. 1994;21:1165–1167
  89. Fawaz-Estrup F. Human parvovirus infection: rheumatic manifestations, angioedema, C1 esterase inhibitor deficiency, ANA positivity, and possible onset of systemic lupus erythematosus. Journal of Rheumatology. 1996;23:1180–1185
  90. Tanaka A, Sugawara A, Sawai K, Kuwahara T. Human parvovirus B19 infection resembling systemic lupus erythematosus. Internal Medicine. 1998;37:708–710
  91. Hemauer A, Beckenlehner K, Wolf H, et al. Acute parvovirus B19 infection in connection with a flare of systemic lupus erythematodes in a female patient. Journal of Clinical Virology. 1999;14:73–77
  92. Magro CM, Crowson NA, Dawood M, Nuovo G. Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune disease. Journal of Rheumatology. 2002;29:1227–1235
  93. Bengtsson A, Widell A, Elmstahl S, et al. No serological indications that systemic lupus erythematosus is linked with seroexposure to human parvovirus B19. Annals of the Rheumatic Diseases. 2000;59:64–66
  94. Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. Journal of Medical Microbiology. 2004;53:459–475
  95. Doyle S, Kerr S, O'Keefe G, et al. Detection of parvovirus B19 IgM by antibody capture enzyme immunoassay: receiver operating characteristic analysis. Journal of Virological Methods. 2000;90:143–152
  96. Heegaard ED, Petersen BL, Heilmann CJ, Hornsleth A. Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from helthy individuals. Journal of Clinical Microbiology. 2002;40:933–936
  97. Söderlund M, Brown CS, Spaan WJ, et al. Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity. Journal of Infectious Diseases. 1995;171:710–713
  98. Kaikkonen L, Lankinen H, Harjunpää I, et al. Acute-phase-specific heptapeptide epitope for diagnosis of parvovirus B19 infection. Journal of Clinical Microbiology. 1999;37:3952–3956
  99. Kaikkonen L, Söderlund-Venermo M, Brunstein J, et al. Diagnosis of human parvovirus B19 infections by detection of epitope-type-specific VP2-IgG. Journal of Medical Virology. 2001;64:360–365
  100. Erdman DD, Durigon EL, Holloway BP. Detection of human parvovirus B19 DNA PCR products by RNA probe hybridization enzyme immunoassay. Journal of Clinical Microbiology. 1994;32:2295–2298
  101. Mendelson E, Aboudy Y, Smetana Z, et al. Laboratory assessment and diagnosis of congenital viral infections: Rubella, cytomegalovirus (CMV), varicella-zoster virus (VZV), herpes simplex virus (HSV), parvovirus B19 and human immunodeficiency virus (HIV). Reproductive Toxicology. 2006;21:350–382
  102. Lindblom A, Isa A, Norbeck O, et al. Slow clearance of human parvovirus B19 viremia following acute infection. Clinical Infectious Diseases. 2005;41:1201–1203
  103. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. Journal of Infectious Diseases. 1985;152:257–265
  104. Tang ML, Kemp AS, Moaven LD. Parvovirus B19-associated red blood cell aplasia in combined immunodeficiency with normal immunoglobulins. The Pediatric Infectious Disease Journal. 1994;13:539–542
  105. Tolfvenstam T, Oxenius A, Price DA, et al. Direct ex vivo measurement of CD8+ T-lymphocyte responses to human parvovirus B19. Journal of Virology. 2001;75:540–543
  106. Klenerman P, Tolfvenstam T, Price DA, et al. T lymphocyte responses against human parvovirus B19: small virus, big response. Pathologie-Biologie. 2002;50:317–325
  107. Norbeck O, Isa A, Pöhlmann C, et al. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infections in humans. Journal of Virology. 2005;79:12117–12121
  108. Von Poblotzki A, Gerdes C, Reischl U, et al. Lymphoproliferative responses after infection with human parvovirus B19. Journal of Virology. 1996;70:7327–7333
  109. Corcoran A, Doyle S, Waldron D, et al. Impaired gamma interferon responses against parvovirus B19 by recently infected children. Journal of Virology. 2000;74:9903–9910
  110. Franssila R, Hokynar K, Hedman K. T-helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus B19. Journal of Infectious Diseases. 2001;183:805–809
  111. Franssila R, Hedman K. T-helper cell mediated interferon-γ, interleukin-10, and proliferation responses to a candidate recombinant vaccine for human parvovirus B19. Vaccine. 2004;22:3809–3815
  112. Franssila R, Auramo J, Modrow S, et al. T-helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2–Specific and transient VP1u–specific activity. Clinical and Experimental Immunology. 2005;142:53–61
  113. Murai C, Munakata Y, Takahashi Y, et al. Rheumatoid arthritis after human parvovirus B19 infection. Annals of Rheumatic Diseases. 1999;58:130–132
  114. Lehmann HW, Plentz A, Von Landenberg P, et al. Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection. Arthritis Research & Therapy. 2004;6:R1–R6
  115. Bansal GP, Hatfield JA, Dunn FE, et al. Candidate recombinant vaccine for human B19 parvovirus. Journal of Infectious Diseases. 1993;167:1034–1044
  116. Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant vaccine parvovirus B19 vaccine formulated with MF59C.A. Journal of Infectious Diseases. 2003;187:675–678
  117. Mantke OD, Nitsche A, Meyer R, et al. Analysis of myocardial tissue from explanted hearts of heart transplant recipients and multi-organ donors for the presence of parvovirus B19 DNA. Journal of Clinical Virology. 2004;31:32–39
  118. Strauss JH, Strauss EG. The alphaviruses: gene expression, replication and evolution. Clinical Microbiology Reviews. 1994;58:491–562
  119. Harley D, Sleigh A, Ritchie S. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clinical Microbiology Reviews. 2001;14:909–932
  120. Suhrbier A, La Linn M. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Current Opinion in Rheumatology. 2004;16:374–379
  121. Laine M, Luukkainen R, Toivanen A. Sindbis virus and other human alphaviruses as a cause of human arthritic disease. Journal of Internal Medicine. 2004;256:457–471
  122. Calabrese LH, Naides SJ. Viral arthritis. Infectious Disease Clinics of North America. 2005;19:963–980
  123. Luukkainen R, Laine M, Nirhamo J. Chronic arthritis after Sindbis-related (Pogosta) virus infection. Scandinavian Journal of Rheumatology. 2000;29:399–400
  124. Kurkela S, Manni T, Myllynen J, et al. Clinical and laboratory manifestations of Sindbis virus infection: prospective study, Finland, 2002–2003. Journal of Infectious Diseases. 2005;191:1820–1829
  125. Turunen M, Kuusisto P, Uggeldahl PE, Toivanen A. Pogosta disease: clinical observations during an outbreak in the province of North Karelia, Finland. British Journal of Rheumatology. 1998;37:1177–1180
  126. Rulli NE, Suhrbier A, Hueston L, et al. Ross River Virus: molecular and cellular aspects of disease pathogenesis. Pharmacology & Therapeutics. 2005;107:329–342
  127. Naides SJ, et al. Viral arthritis. In:  Hochberg MC,  Silman AJ,  Smolen AJ editor. 3rd edn. Rheumatology. London: Mosby; 2003;p. 1105–1113
  128. Journeaux SF, Brown WG, Aaskov JG. Prolonged infection of human synovial cells with Ross River virus. The Journal of General Virology. 1987;68:3165–3169
  129. Soden MH, Vasudevan H, Roberts B, et al. Detection of viral ribonucleic acid and histologic analysis of inflamed synovium in Ross River virus infection. Arthritis and Rheumatism. 2000;43:365–369
  130. Morrison TE, Whitmore AC, Shabman RS, et al. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. Journal of Virology. 2006;80:737–749
  131. La Linn M, Mateo L, Gardner J, Suhrbier A. Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages. Journal of Virology. 1998;72:5146–5153
  132. Way SJR, Lidbury BA, Banyer JL. Persistent Ross River virus infection of murine macrophages: an in vitro model for the study of viral relapse and immune modulation during long-term infection. Virology. 2002;301:281–292
  133. La Linn M, Eble JA, Lubken C, et al. An arthritogenic alphavirus uses the alpha1beta1 integrin collagen receptor. Virology. 2005;336:229–239
  134. Mahalingam S, Lidbury BA. Suppression of lipopolysaccharide-induced antiviral transcription factor (STAT-1 and NF-kappa B) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proceedings of the National Academy of Science USA. 2002;21:13819–13824
  135. Ryman KD, Klimstra WB, Nguyen KB, et al. Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. Journal of Virology. 2000;74:3366–3378
  136. Wolinsky JS. Rubella. In:  Fields BN,  Knipe DM,  Howley PM editor. Fields virology. 4th edn. Philadelphia, PA: Lippincott, Williams and Wilkins; 1996;p. 899–929
  137. Banatvala JE, Brown DWG. Rubella. Lancet. 2004;363:1127–1136
  138. Sauter S, Utsinger PD. Viral arthritis. In:  Schmid FR editors. Clinics in rheumatic diseases. vol. 4:London: W.B. Saunders Company LTD; 1978;p. 225–238
  139. Cunningham AL, Fraser JR. Persistent rubella virus infection of human synovial cells cultured in vitro. Journal of Infectious Diseases. 1985;151:638–645
  140. Green KY, Dorsett PH. Rubella virus antigens: localization of epitopes involved in hemagglutination and neutralization by using monoclonal antibodies. Journal of Virology. 1986;57:893–898
  141. Corboba P, Grutadauria S, Cuffini C, Zapata M. Neutralizing monoclonal antibody to the E1 glycoprotein epitope of rubella virus mediates virus arrest in VERO cells. Viral Immunology. 2000;13:83–92
  142. Chaye H, Ou D, Chong P, Gillam S. Human T- and B-cell epitopes of E1 glycoprotein of rubella virus. Journal of Clinical Immunology. 1993;13:93–100
  143. Mitchell LA, Decarie D, Tingle AJ, et al. Identification of immunoreactive regions of rubella virus E1 and E2 envelope proteins by using synthetic peptides. Virus Research. 1993;29:33–57
  144. Marttila J, Ilonen J, Lehtinen M, et al. Definition of three minimal T helper cell epitopes of rubella virus E1 glycoprotein. Clinical and Experimental Immunology. 1996;104:394–397
  145. Nedeljkovic J, Jovanovic T, Mladjenovic S, et al. Immunoblot analysis of natural and vaccine-induced IgG responses to rubella virus proteins expressed in insect cells. Journal of Clinical Virology. 1999;14:119–131
  146. Ou D, Chong P, Tripet B, Gillam S. Analysis of T- and B-cell epitopes of capsid protein of rubella virus by using synthetic peptides. Journal of Virology. 1992;66:1674–1681
  147. Ou D, Mitchell LA, Decarie D, et al. Characterization of an overlapping CD8+ and CD4+ T-cell epitope on rubella capsid protein. Virology. 1997;235:286–292
  148. Lovett AE, Hahn CS, Rice CM, et al. Rubella virus-specific cytotoxic T-lymphocyte responses: identification of the capsid as a target of major histocompatibility complex class I-restricted lysis and definition of two epitopes. Journal of Virology. 1993;67:5849–5858
  149. Chantler JK, Ford DK, Tingle AJ. Persistent rubella infection and rubella-associated arthritis. Lancet. 1982;1:1323–1325
  150. Hedman K, Seppälä I. Recent rubella virus infection indicated by a low avidity low avidity of specific IgG. Journal of Clinical Immunology. 1988;8:214–221
  151. Geiger R, Fink FM, Solder B, et al. Persistent rubella infection after erroneous vaccination in an immunocompromised patient with acute lymphoblastic leukemia in remission. Journal of Medical Virology. 1995;47:442–444
  152. Masuko-Hongo K, Kato T, Nishioka K. Virus-associated arthritis. Best Practise and Research Clinical Rheumatology. 2003;17:309–318
  153. Mody GM, Parke FA, Reveille JD. Articular manifestations of human immunodeficiency virus infection. Best Practice and Research Clinical Rheumatology. 2003;2:265–287

PII: S1521-6942(06)00111-2

doi: 10.1016/j.berh.2006.08.007

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 6 , Pages 1139-1157 , December 2006

Article Tools